AKR1A1 is an aldehyde reductase that is associated with resistance to radiotherapy and chemotherapy in laryngeal cancer, breast cancer, etc.; however, there have been no similar studies for pancreatic cancer. Here, AKR1A1 is linked to laryngeal carcinoma.